Ar­genx launch­es $750M of­fer­ing af­ter PhII da­ta drop

Dutch biotech ar­genx launched a $750 mil­lion of­fer­ing the same day it shared promis­ing da­ta from a Phase II study test­ing its on­ly ap­proved drug as a treat­ment for a rare neu­ro­log­i­cal dis­or­der.

The com­pa­ny al­so said Mon­day evening that in­vest­ment firm Bail­lie Gif­ford Over­seas Lim­it­ed is in­ter­est­ed in pur­chas­ing up to $200 mil­lion in shares as part of the of­fer­ing.

Its shares $ARGX jumped about 6% in trad­ing on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER